BIND Therapeutics, a Cambridge nanomedicine company developing programmable drugs, said Monday that it has dosed the first patient in a Phase 2 clinical trial of BIND-014 as a second-line therapy in patients with non-small cell lung cancer.
The company is using a nano-engineering platform to develop Accurins, programmable therapeutics designed to target specific cells or tissues and concentrate a drug payload at the site of disease. The thinking is that this approach will enhance the effectiveness of the treatment while minimizing adverse effects on healthy tissues.
BIND-014 represents the first Accurin nanomedicine to reach the clinic from the company’s “Medicinal Nanoengineering platform,” the company said in a press release. In pre-clinical studies, BIND said it has been able to demonstrate that Accurins can improve tumor growth suppression and achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form.
In a statement, BIND chief medical officer Gregory Berk, MD, said: “There are limited options for patients with advanced non-small cell lung cancer in the second-line setting. We are pleased our Phase 1 trial of BIND-014 established the safety profile and appropriate Phase 2 dose for this drug candidate, and we are advancing BIND-014 into Phase 2 development to further evaluate its clinical activity as a potential treatment option for patients who are in need of more effective therapies.”
BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.